Classical Neurotransmitters and Neuropeptides Involved in Major Depression: a Review

REFERENCES

• Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology, 32(9), 1888–1902.
   PubMed Web of Science ®Google Scholar
• Berlanga, C., & Flores-Ramos, M. (2006). Different gender responses to serotonergic and noradrenergic antidepressant: A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders, 95(1–3), 119–123.
   PubMedGoogle Scholar
• Bielau, H., Steiner, J., Mawrin, C., Trubner, K., Brisch, R., Meyer-Lotz, G., (2007). Dysregulation of GABAergic neurotransmission in mood disorders: A postmortem study. Annals of the New York Academy of Sciences, 1096, 157–169.
   PubMedGoogle Scholar
• Blier, P., Gobbi, G., Haddjiri, N., Santarelli, L., Mathew, G., & Hen, R. (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response. Journal of Psychiatry & Neuroscience, 29(3), 208–218.
   PubMed Web of Science ®Google Scholar
• Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., (2007). Selective blockade of 5-HT7 receptors enhances 5-HT neurotransmission, antidepressant-like behavior and REM sleep suppression induced by citalopram in rodents. The Journal of Pharmacology and Experimental Therapeutics, 321(2), 690–698.
   PubMed Web of Science ®Google Scholar
• Brundin, L., Björkqvist, M., Petersén, A., & Traskman-Bendz, C. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology, 17(9), 573–579.
   PubMed Web of Science ®Google Scholar
• Bschor, T., Lewitzka, U., Sasse, J., Adli, M., Koberle, U., & Bauer, M. (2003). Lithium augmentation in treatment-resistant depression: Clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry, 36(Suppl. 3), 230–234.
   Google Scholar
• Cervilla, J. A., Molina, E., Rivera, M., Torres-González, F., Bellón, J. A., Moreno, B., (2007). The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5-HTTLPR genotype: Evidence from the Spanish PREDICT Gen cohort. Molecular Psychiatry, 12(8), 748–755.
   PubMedGoogle Scholar
• Chen, C., Wilcoxen, K. M., Huang, C. Q., Wie, Y. F., McCarthy, J. R., Webb, T. R., (2004). Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidini (NBI 30775/R 121919) and structure–activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. Journal of Medicinal Chemistry, 47(19), 4787–4798.
   PubMedGoogle Scholar
• Clayton, A. H. (2007). Extended-release bupropion: An antidepressant with a broad spectrum of therapeutic activity? Expert Opinion on Pharmacotherapy, 8(4), 457–466.
   PubMed Web of Science ®Google Scholar
• Deuschle, M., Sander, P., Hernfer, I., Fiebich, B. L., Heuser, I., & Lieb, K. (2005). Substance P and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment. Psychiatry Research, 136(1), 1–6.
   PubMed Web of Science ®Google Scholar
• de Winter, R. F., Ziman, F. G., von Houwelingen, J. C., Wolterbeek, R., & Goekoop, J. G. (2006). Anxious-retarded depression: Relation to two-year outcome of major depressive disorder. Journal of Affective Disorders, 90(1), 77–81.
   PubMedGoogle Scholar
• Earnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., (2007). GABAergic control of adult hippocampal neurogenesis in relation to behaviour indicative of trait anxiety and depression states. The Journal of Neuroscience, 27(14), 3845–3854.
   PubMedGoogle Scholar
• Eser, D., Schüle, C., Baghai, T. C., Romero, E., Uzunov, D. P., & Rupprecht, R. (2006). Neuroactive steroids and affective disorders. Pharmacology, Biochemistry, and Behavior, 84(4), 656–666.
   PubMedGoogle Scholar
• Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006). Bupropion: Pharmacology and therapeutic applications. Expert Review of Neurotherapeutics, 6(9), 1249–1265.
   PubMed Web of Science ®Google Scholar
• Frieling, H., Hillemacher, T., Demling, J. H., Kornhuber, J., & Bleich, S. (2007). New options in the treatment of depression. Fortschritte der Neurologie-Psychiatrie, 75(11), 641–652.
   PubMedGoogle Scholar
• García-Colunga, J., Vázquez-Gómez, E., & Miledi, R. (2004). Combined actions of zinc and fluoxetine in nicotinic acetylcholine receptors. Pharmacogenomics, 4(6), 388–393.
   Google Scholar
• Gendall, K. A., Joyce, P. R., Mulder, R. I., & Luty, S. E. (2003). Thyroid indices and response to fluoxetine and nortriptyline in major depression. Journal of Psychopharmacology, 17(4), 431–437.
   PubMedGoogle Scholar
• Geracioti, T. D., Jr., Carpenter, L. L., Owens, M. J., Baker, D. G., Eklator, N. N., Horn, P. S., (2006). Elevated cerebrospianl fluid substance P concentrations in posttraumatic stress disorder and major depression. The American Journal of Psychiatry, 163(4), 637–643.
   PubMed Web of Science ®Google Scholar
• Gervasoni, N., Bertscho, G., Osieka, C., Pernet, G., Devis, R., Golaz, J., (2004). Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. Journal of Psychiatric Research, 38(6), 553–557.
   PubMedGoogle Scholar
• Godin, O., Dufouil, C., Ritchie, K., Dartigues, J. F., Tzourio, C., Peres, K., (2007). Depressive symptoms, major depressive episode and cognition in the elderly: The three-city study. Neuroepidemiology, 28(2), 101–108.
   PubMedGoogle Scholar
• Goekoop, J. G., de Winter, R. P., de Rijk, R., Zwindermann, K. H., Frankhuijzen-Sierevogel, A., & Wiegant, W. M. (2006). Depression with above-normal plasma vasopressin validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Research, 141(2), 201–211.
   PubMedGoogle Scholar
• Hasler, G., Van Der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Prevets, W. C. (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using positron magnetic resonance spectroscopy. Archives of General Psychiatry, 64(2), 193–200.
   PubMed Web of Science ®Google Scholar
• Hebb, A. L., Poulin, J. E., Roach, S. P., Zacharko, R. M., & Drolet, G. (2005). Cholecystokinin and endogenous opioid peptides: Interactive influence on pain, cognition, and emotion. Progress in Neuropsychopharmacology and Biological Psychiatry, 29(8), 1225–1238.
   PubMedGoogle Scholar
• Held, K., Antonijivic, I., Murck, H., Kuenzel, H., & Steiger, A. (2006). Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology, 31(1), 100–107.
   PubMedGoogle Scholar
• Hemmeter, U., Hatzinger, M., Brand, S., & Holsboer-Trachsler, E. (2006). Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation. Journal of Psychiatric Research, 41(10), 876–884.
   PubMedGoogle Scholar
• Hettema, J. M., An, S. S., Neale, M. C., Bukszar, J., Van Der Oord, E. J., Kendler, K. S., (2006). Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Molecular Psychiatry, 11(8), 752–762.
   PubMed Web of Science ®Google Scholar
• Hou, C., Jia, F., Liu, Y., & Li, L. (2006). CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Research, 1095(1), 154–158.
   PubMed Web of Science ®Google Scholar
• Isogawa, K., Nagayama, H., Tsutsumi, T., Kiyota, A., Akiyoshi, J., & Hieda, K. (2005). Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropin-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder. Journal of Psychiatric Research, 39(5), 467–473.
   PubMedGoogle Scholar
• Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., (2006). Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry, 59(3), 216–233.
   PubMedGoogle Scholar
• Kennedy, S. E., Koeppe, R. A., Young, E. A., & Zubieta, J. K. (2006). Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Archives of General Psychiatry, 63(11), 1199–1208.
   PubMedGoogle Scholar
• Kim, H., Lim, S. W., Kim, S., Kim, J. W., Chang, Y. H., Carroll, B. J., (2006). Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA: The Journal of the American Medical Association, 296(13), 1603–1618.
   Google Scholar
• Kornum, B. R., Weikop, P., Moller, A., Ronn, L. C., Knudsen, G. M., & Aznar, S. (2006). Serotonin depletion reuptake in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Research, 262(8), 1073–1074.
   Google Scholar
• Kunugi, H., Ida, I., Owaski, T., Kimura, M., Inoue, Y., Nakagawa, S., (2006). Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study. Neuropsychopharmacology, 31(1), 212–220.
   PubMedGoogle Scholar
• Kunzel, H. E., Zobel, A. W., Nickel, T., Ackl, N., Uhr, M., Sonntag, A., (2003). Treatment of depression with the CRH-1-receptor antagonist R 121919: Endocrine changes and side effects. Journal of Psychiatric Research, 37(6), 525–533.
   PubMedGoogle Scholar
• Lai, I. C., Hong, C. J., & Tasi, S. J. (2001). Association study of nicotinic-receptor variants and major depressive disorders. Journal of Affective Disorders, 66(1), 79–82.
   PubMedGoogle Scholar
• Lemos, J. C., Pan, Y. Z., Ma, X., Lamy, C., Akanowa, A. C., & Buch, S. G. (2006). Selective 5-HT receptor inhibition of glutaminergic and GABAergic synaptic activity in the rat dorsal and median raphe. The European Journal of Neuroscience, 24(12), 3415–3430.
   PubMedGoogle Scholar
• Leonard, B. E. (2005). The HPA and immune axes in stress: The involvement of the serotonergic system. European Psychiatry, 20(Suppl. 3), S302–S306.
   PubMed Web of Science ®Google Scholar
• Lieb, K., Fiebich, B. L., Herpfer, I., Mantovani, M., Loffler, M., & Feuerstein, T. J. (2005). No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. European Neuropsychopharmacology, 15(6), 641–646.
   PubMedGoogle Scholar
• Lieb, K., Walden, J., Grunze, H., Fiebich, B. L., Berger, M., & Normann, C. (2004). Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry, 37(5), 238–239.
   PubMedGoogle Scholar
• Liu, G. X., Cai, G. Q., Cai, Y. Q., Sheng, Z. J., Jiang, J., Mei, Z., (2006). Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology, 32(7), 1531–1539.
   PubMedGoogle Scholar
• Lu, X., Barr, A. M., Kinney, J. W., Sanna, P., Conti, B., Behrens, M. M., et al. (2005). A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proceedings of the National Academy of Sciences of the United States of America, 102(3), 874–879.
   Google Scholar
• Mendlewicz, J., Oswald, P., Claes, S., Massat, I., Souery, D., Van Broeckhoven, C., (2005). Patient–control association study of substance P-related genes in unipolar and bipolar affective disorders. The International Journal of Neuropsychopharmacology, 8(4), 505–513.
   PubMedGoogle Scholar
• Merali, Z., Kent, P., Du, L., Hodinga, P., Palkovits, M., Faludi, G., (2006). Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biological Psychiatry, 59(7), 594–602.
   PubMedGoogle Scholar
• Meyer, J. H., McNeely, H. F., Sagrati, S., Boovariwala, A., Martin, K., Verhoeff, N. P., (2006). Elevated putamen D(2) receptor binding potential in major depression with motor retardation: An [11C] raclopride positron emission tomography study. The American Journal of Psychiatry, 163(9), 1594–1602.
   PubMedGoogle Scholar
• Meynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., & Hoogendijk, W. J. (2006). Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biological Psychiatry, 60(8), 892–895.
   PubMedGoogle Scholar
• Navines, R., Martín-Santos, R., Gómez-Gil, E., Martínez de Osaba, M. J., Imaz, M. L., & Gasto, L. (2007). Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT(1A) receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology, 32(3), 307–312.
   Google Scholar
• Newberg, A., Amsterdam, J., & Shults, J. (2007). Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nuclear Medicine Communications, 28(1), 3–6.
   PubMedGoogle Scholar
• Nierenberg, A. A., Greist, J. H., Mallinckrodt, G. D., Prakash, A., Sambunaris, A., Topllefion, G. D., (2007). Dulexetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, non-inferiority study. Current Medical Research and Opinion, 23(2), 401–416.
   PubMed Web of Science ®Google Scholar
• Nikisch, G., Agren, H., Eap, C. B., Czernik, A., Baumann, P., & Mathe, A. A. (2005a). Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. The International Journal of Neuropsychopharmacology, 8(3), 403–410.
   PubMed Web of Science ®Google Scholar
• Nikisch, G., Mathe, A. A., Czernik, A., Thiele, J., Bohner, J., Eap, C. B., (2005b). Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: Relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology, 181(4), 751–760.
   PubMedGoogle Scholar
• Nowak, G., Partyka, A., Palucha, A., Szawczyk, B., Wieronska, J. M., Dybate, M., (2006). Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British Journal of Pharmacology, 149(5), 581–590.
   PubMedGoogle Scholar
• Nutt, D. J., Baldwin, D. S., Clayton, A. H., Elgie, R., Lecrubier, Y., Montejo, A. L., (2006). Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment. The Journal of Clinical Psychiatry, 67(6), 46–49.
   PubMedGoogle Scholar
• Nutt, D. J., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., (2007). The other face of depression, reduced positive effect: The role of catecholamines in causation and cure. Journal of Psychopharmacology, 21(5), 461–471.
   PubMed Web of Science ®Google Scholar
• Pae, L. U., Serretti, A., Mandelli, L., De Ronchi, P., Pathar, A. A., Jun, T. Y., (2007). Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics and Genomics, 17(1), 69–79.
   PubMedGoogle Scholar
• Palucha, A. (2006). Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opinion on Investigational Drugs, 15(12), 1545–1553.
   PubMed Web of Science ®Google Scholar
• Rosenzweig-Lipson, S., Sabb, A., Stack, G., Mitchell, P., Lucki, I., Malberg, J. E., (2007). Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-16309 in rodents. Psychopharmacology, 192(2), 159–170.
   PubMed Web of Science ®Google Scholar
• Ruhe, H. G., Mason, N.S., & Schene, A.H. (2007). Mood is directly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Molecular Psychiatry, 12(4), 331–359.
   PubMed Web of Science ®Google Scholar
• Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Tenton, L. R., Covic, V., (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry, 61(6), 822–825.
   PubMed Web of Science ®Google Scholar
• Sánchez, C., Brennum, L. T., Stórustovu, S., Kreilgard, M., & Mork, A. (2007). Depression and poor sleep: The effect of monoaminergic antidepressant in a pre-clinical model in rats. Pharmacology, Biochemistry, and Behavior, 86(3), 468–476.
   PubMed Web of Science ®Google Scholar
• Schüle, C., Baghai, T. C., Alajbegovic, L., Schwarz, M., Zwanzger, P., Eser, D., (2005). The effect of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 255(5), 334–340.
   PubMedGoogle Scholar
• Schüle, C., Baghai, T. C., Eser, D., Zwanzger, P., Jordan, M., Buechs, R., (2006). Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtrazapine in depressed patients. Psychopharmacology (Berlin), 186(4), 601–611.
   PubMedGoogle Scholar
• Sergeyev, V., Tetivsov, S., Mathe, A. A., Jiménez, P. A., Bartfai, T., Mortas, P., (2005). Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berlin), 178(2–3), 115–124.
   PubMedGoogle Scholar
• Sinei, K. A., & Redfern, P. H. (1993). The effects of chronic clomipramine and mianserin on the activity of tryptophan hydroxylase in the rat brain. East African Medical Journal, 70(11), 721–724.
   PubMedGoogle Scholar
• Skolnick, P., Krieter, P., Tizzano, J., Basile, A., Popik, P., Czolor, P., (2006). Preclinical and clinical pharmacology of DOV 216 303, a “triple” reuptake inhibitor. CNS Drug Reviews, 12(2), 123–134.
   PubMedGoogle Scholar
• Stone, E. A., Quartermain, D., Lin, Y., & Lehmann, M. L. (2006). Central alpha(1)-adrenergic system in behavioral activity and depression. Biochemical Pharmacology, 73(8), 1063–1075.
   PubMedGoogle Scholar
• Szuba, M. P., Amsterdam, J. D., Fernando, A. T., 3rd, Gary, K. A., Whybrow, P. C., & Winokuv, A. (2005). Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. Journal of Clinical Psychopharmacology, 25(4), 325–330.
   PubMedGoogle Scholar
• Taner, E., Demin, E. Y., & Cosar, B. (2006). Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial. Advances in Therapy, 23(6), 974–987.
   PubMedGoogle Scholar
• Thase, M. E., Clayton, A. H., Haight, B. R., Thompson, H. H., Modell, J. G., & Johnston, J. A. (2006). A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. Journal of Clinical Psychopharmacology, 26(5), 482–488.
   PubMed Web of Science ®Google Scholar
• Thompson, S. E., Ayman, G., Woodhall, G. L., & Jones, R. S. (2007). Depression of glutamate and GABA release by presynaptic GABA(B) receptors in the entorhinal cortex in normal and chronically epileptic rats. Neurosignals, 15(4), 202–215.
   Google Scholar
• Tordera, R. M., Tottendell, S., Wojcik, S. M., Brose, N., Elizade, N., Lasheras, B., (2007). Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter gene 1 (VGLLT 1). The European Journal of Neuroscience, 25(1), 281–290.
   PubMedGoogle Scholar
• Wang, J. C., Hinrichs, A. L., Stock, H., Budde, J., Allen, R., Bertelsen, S., (2004). Evidence of common and specific genetic effects: Association of muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Human Molecular Genetics, 13(17), 1903–1911.
   PubMed Web of Science ®Google Scholar
• Werner, F. M. (2004). Theoretical reflections about the reciprocal influence of neurotransmitters upon each other. Klinická Neurologie, 35, 125–222.
   Google Scholar
• Werner, F. M. (2006). Schizophrenia: From the genetic localization to the cellular mechanism. Klinická Neurologie, 37, 19–107.
   Google Scholar
• Werner, F. M. (2007). Classical neurotransmitters involved in Parkinson's disease. Journal of Neural Transmission, 114, I–XXXI.
   Google Scholar
• Werner, F. M., & Coveñas, R. (2005). Neuropeptides involved in schizophrenia. Current Topics in Neurochemistry, 4, 35–49.
   Google Scholar
• Werner, F. M., & Coveñas, R. (2007). Neuropeptides and classical neurotransmitters involved in Parkinson and Alzheimer diseases. In R. Coveñas, A. Mangas, and J. A. Narváez (eds.), Focus on Neuropeptide Research. Trivandrum: Transworld Research Network, 299–339.
   Google Scholar
• Wheatland, R. (2005). Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic–pituitary–adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Medical Hypotheses, 65(2), 287–295.
   PubMedGoogle Scholar
• Zhou, J. (2004). Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future, 29(12), 1235–1244.
   PubMed Web of Science ®Google Scholar